期刊文献+

TP与DF化疗方案治疗鼻咽癌肝、肺转移的疗效比较 被引量:9

Comparison of the Effect of Paclitaxel and 5-Fluorouracil Combined with Cisplatin in the Treatment of Liver and Lung Metastasis Tumors from Advanced Nasoplaryngeal Carcinoma
下载PDF
导出
摘要 目的探讨紫杉醇(paclitaxel)+顺铂(cisplatin,DDP;TP方案)与5-氟脲嘧啶(5-Fluorouracil,5-Fu)+DDP(DF方案)治疗晚期鼻咽癌肝、肺转移的客观疗效及毒副作用。方法对56例共211个疗程TP(30例)或DF(26例)方案化疗的鼻咽癌肝、肺转移病例的临床疗效及其副作用进行了回顾性分析比较。同一化疗方案的病例列为一组,即分为TP组(30例)和DF组(26例)。两组均以3周为1个疗程,至少接受2个疗程化疗。分别总结两组的有效率,中位生存期和白细胞数、血小板计数,恶心、呕吐、腹泻、口腔炎、脱发等副反应的发生构成比,并进行统计、分析。结果TP方案组的总有效率为73.33%,明显高于DF方案组的46.15%(P<0.05);TP组和DF组中位生存期分别为11.8个月和9.8个月,但经Logrank检验无明显差异性(P>0.05)。治疗毒副反应,TP组以脱发(100%)、白血球下降(83.33%)和血小板下降(50%)为主。而DF组则以恶心、呕吐(76.92%)、腹泻(73.07%)、口腔炎(46.15%)等消化道反应明显。结论TP方案治疗晚期鼻咽癌肝、肺转移疗效明显优于DF方案,中位生存期TP组也高于DF组。毒副反应各自有别,但均以Ⅰ、Ⅱ度反应明显,患者均可接受。 Objective To explore the effect and toxic side-effect of paclitaxel plus cisplatin(TP regiment) and 5-Fluoreracil plus cisplatin combination chemotherape in the treatment of liver and lung metastasis tumors from advanced nasoplaryngeal cancer. Methods 56 patients who received 2ll course treatment with TP(30 cases) or DF (26 eases) regiment were retrospectively analyzed and compared the toxic side-effect. The patients were divided two groups. The first group with 30 patients was treated with TP regiment. The second group with 26 patients was treated with DF regiment. Each treatment cycle was three weeks. Each patient received no less than 2 courses of treatment. It was anlayzed the effective median survival time and the proportion of main side-effect which was determined by the leucocyte quantity, platelet quantity, nausea, vomiting, diarrhoea, mucositis and alopecia. Results It shows the effective rate of TP regiment was 73.33%, which was apparently higher than 46.15%(P〈0.05) in DF regiment group. The median survival time was 11.8 and 9.8 months in TP and DF regiment group, respectively. But the difference was not significant when analyzed by logrank study (P〉0.05). The main toxic side-effects were alopecia (100%), leucocyte reduction (83.33%) and platelet reduction (50%) in TP regiment group. The obvious side-effects in DF regiment were nausea and vomiting (76.92%), diarrhea (73.07%) and mucositis (46.15%). Conclusion The treatment effect and median survival in TP regiment group were apparently higher than those in DF regiment group. The toxic side-effects were tolerable and mild.
出处 《热带医学杂志》 CAS 2006年第2期156-158,共3页 Journal of Tropical Medicine
关键词 鼻咽癌 肝肺转移/药物疗法 紫杉醇 5-氟脲嘧啶 联合用药 nasopharyngeal cancer liver and lung metastasis/drug therapy paclitaxel 5-Fluuorourasil combined chemotherapy
  • 相关文献

参考文献7

二级参考文献16

  • 1[1]Woo MH,Relling MV,Sonnichsen DS.Phase 1 targeted systemic exposure study of paclitaxel in children with refractory acute leukemias [J].Clin Cancer Res ,1999,5(3) :543-549.
  • 2Raymond E,Chaney SG,Taamma A,et al. Oxaliplatin: a review of preclinical and clinical studies [J]. Ann Oncol,1998,9(10):1053- 1071.
  • 3Rixe O,Ortuzar W,Alvarez M,et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug resistant cell lines and in the cell lines of the national cancer institute's anticancer drug screen panel [J]. Biochem Pharmacol,1996,52(12):1855- 1859.
  • 4Monnet I,Brienza S,Hugret F,et al. Phase Ⅱ study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC). AT-TIT. Association pour le Traitement des Tumeurs Intra Thoraciques [J]. Eur J Cancer,1998, 34(7):1124- 1127.
  • 5Faivre S,Kalla S,Cvitkovic E,et al. Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma:an investigator-originated compassionate-use experience [J]. Ann Oncol,1999, 10(9):1125- 1128.
  • 6Jamieson SM,Liu J,Hsu T,et al. Paclitaxel induces nuckeolar enlargement in dorsal root ganglion neurons in vivo reducing oxaliplatin toxicity [J]. Br J Cancer,2003, 88(12):1942- 1947.
  • 7Liu J,Kraut EH,Balcerzak S,et al. Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat [J]. Cancer Chemother Pharmacol,2002, 50(6):445- 453.
  • 8Maiche AG,Jekunen AP,Kaleva Kerola J,et al.High response rate with a lower dose of paclitaxel in combination with cisplatin in heavily pretreated patients with advanced breast carcinoma [J].Cancer,2000,88(8):1863- 1868.
  • 9Ando M,Watanabe T,Nagata K,et al.Efficacy of docetaxel 60 mg/m2 in patients with metastatic breast cancer according to the status of anthracycline resistance [J].J Clin Oncol,2001,19(2):336- 342.
  • 10Vici P,Belli F,Di Lauro L,et al.Docetaxel in patients with anthracycline resistant advanced breast cancer [J].Oncology,2001,60(1):60- 65.

共引文献95

同被引文献75

引证文献9

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部